rituximab biosimilar / AzarGen - LARVOL DELTA

IBio supports AzarGen Bio to develop rituximab biosimilar (SeekingAlpha) - "iBio (NYSEMKT:IBIO) has entered into a second Statement of Work under its Master Joint Development Agreement (the 'MJDA') with AzarGen Biotechnologies....The company plans to transfer its FastPharming Manufacturing System to AzarGen in South Africa for production of critical biological medicines for the African continent....Therefore, iBio will now manufacture additional supplies to enable pre-clinical studies comparing plant-made rituximab to the original molecule made using genetically engineered mammalian cells."

Licensing / partnership